Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Initiation Dose Safety and Efficacy in Chinese Acute Schizophrenia
NCT05011669Phase 4Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Started Aug 2021; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05011669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011669.